Testing for Lung Cancer

Transforming Lung Cancer Screening with Proactive Diagnostics

Lung cancer remains one of the leading causes of cancer‑related deaths in the UK, largely because it is often diagnosed at a late stage. Early detection dramatically improves survival rates and reduces the need for aggressive treatment. Traditional screening methods typically identify lung cancer only once a tumour has formed, limiting opportunities for early intervention. Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies risk at the molecular level, long before structural changes appear on imaging.

The HrC test represents a new generation of lung cancer screening—one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into lung cancer risk than conventional methods alone.

Current Methods for Diagnosing Lung Cancer

Lung cancer screening and diagnosis in the UK typically involve several established tools used within the NHS and private healthcare settings:

• Low‑Dose CT (LDCT) Scans: The primary screening tool for high‑risk individuals, used to detect lung nodules or abnormalities.
• Chest X‑ray: Often used in initial assessments but less sensitive for early‑stage disease.
• PET‑CT Scans: Used to investigate suspicious findings and assess cancer spread.
• Bronchoscopy or Biopsy: Procedures that collect tissue samples to confirm malignancy and determine cancer characteristics.

These methods have been essential in improving outcomes, yet they remain reactive—they detect cancer only after visible changes occur.

Limitations of Conventional Lung Cancer Screening

Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:

• Detection Threshold: Imaging can only identify tumours once they reach a detectable size, meaning the earliest stages may remain hidden.
• False Positives: Benign nodules, infections, and scarring can mimic cancer on imaging, leading to unnecessary follow‑up tests and anxiety.
• Invasiveness: Biopsies and bronchoscopies carry risks such as bleeding, infection, and respiratory complications.
• Limited Screening Eligibility: In the UK, LDCT screening is currently offered only to specific high‑risk groups, meaning many cases may go undetected until symptoms appear.

These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms.

The HrC Test: A Breakthrough in Early Lung Cancer Detection

The HrC test introduces a transformative approach to lung cancer screening by focusing on the earliest biological drivers of cancer. Instead of searching for tumours, the test isolates and analyses Cancer Stem Cells (CSCs)—the rare cells responsible for initiating cancer development.

A simple 12ml blood sample enables the HrC test to deliver:

• A 12–18 Month Early Warning Window: Detection of cancer‑initiating molecular activity long before imaging or biopsy can identify a mass.
• High Sensitivity and Clear Results: With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
• Reliable “Safe Zone” Assessment: A clear indication of “no risk” offers reassurance that lung cancer is not present and is unlikely to develop within the next year.

This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.

Comprehensive Cancer Screening Through a Single Test

Pan‑Cancer Detection for Complete Health Protection

Although this article focuses on lung cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.

Key Advantages Include:

• Holistic Health Monitoring: Simultaneous assessment of lung cancer risk alongside other major cancers such as Bladder, Bowel, Breast, Cervical, Kidney, Leukaemia, Liver, Lymphoma, Ovarian, Pancreatic and Prostate.
• Actionable Insights: Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies.
• One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.

Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.

About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here